Terms: = Pancreatic cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
58 results:
1. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With pancreatic cancer Treated With Perioperative Adjuvant Chemotherapy.
Kawahara S; Aoyama T; Murakawa M; Kanemoto R; Takahashi D; Kamioka Y; Hashimoto I; Maezawa Y; Kobayashi S; Ueno M; Yamamoto N; Oshima T; Yukawa N; Rino Y; Saito A; Morinaga S
Anticancer Res; 2024 Apr; 44(4):1711-1718. PubMed ID: 38537971
[TBL] [Abstract] [Full Text] [Related]
2. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
[TBL] [Abstract] [Full Text] [Related]
3. Ex vivo modeling of acquired drug resistance in braf - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.
Steiner S; Pliego-Mendieta A; Haberecker M; Hussung S; Kollár A; Fritsch R; Arnold F; Lenggenhager D; Planas-Paz L; Pauli C
Cancer Lett; 2024 Mar; 584():216650. PubMed ID: 38246222
[TBL] [Abstract] [Full Text] [Related]
4. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation.
Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T
Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686
[TBL] [Abstract] [Full Text] [Related]
5. The EMT factor ZEB1 paradoxically inhibits EMT in braf-mutant carcinomas.
Sánchez-Tilló E; Pedrosa L; Vila I; Chen Y; Győrffy B; Sánchez-Moral L; Siles L; Lozano JJ; Esteve-Codina A; Darling DS; Cuatrecasas M; Castells A; Maurel J; Postigo A
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37870961
[TBL] [Abstract] [Full Text] [Related]
6. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type pancreatic cancer.
Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
[TBL] [Abstract] [Full Text] [Related]
7. Targeted Therapy for braf V600E Positive pancreatic Adenocarcinoma: Two Case Reports.
Shah S; Rana T; Kancharla P; Monga D
Cancer Genomics Proteomics; 2023; 20(4):398-403. PubMed ID: 37400141
[TBL] [Abstract] [Full Text] [Related]
8. Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma.
Wang J; Shi Y; Chen J; Liu J; Zhao X; Pang J; Sun X; Tian Y; Ou Q; Xia F; Chen Y
Cancer Biol Ther; 2023 Dec; 24(1):2223375. PubMed ID: 37337460
[TBL] [Abstract] [Full Text] [Related]
9. Impact of KRAS and braf mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract] [Full Text] [Related]
10. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.
Ye TW; Wang DD; Lu WF; Xie YM; Xu FQ; Fu TW; Zhang KJ; Liu SY; Xie GL; Cheng J; Jiang K; Xiao ZQ; Yao WF; Shen GL; Liu JW; Huang DS; Zhang CW; Liang L
Expert Rev Gastroenterol Hepatol; 2023 Apr; 17(4):395-403. PubMed ID: 36939280
[TBL] [Abstract] [Full Text] [Related]
11. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?
Garcia-Carbonero R; Anton-Pascual B; Modrego A; Del Carmen Riesco-Martinez M; Lens-Pardo A; Carretero-Puche C; Rubio-Cuesta B; Soldevilla B
Endocr Rev; 2023 Jul; 44(4):724-736. PubMed ID: 36879384
[TBL] [Abstract] [Full Text] [Related]
12. Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management.
Liu Z; Xu H; Weng S; Guo C; Dang Q; Zhang Y; Ren Y; Liu L; Wang L; Ge X; Xing Z; Zhang J; Luo P; Han X
Cancer Immunol Immunother; 2023 Mar; 72(3):599-615. PubMed ID: 35998003
[TBL] [Abstract] [Full Text] [Related]
13. Quantitative Pathologic Analysis of Digitized Images of Colorectal Carcinoma Improves Prediction of Recurrence-Free Survival.
Pai RK; Banerjee I; Shivji S; Jain S; Hartman D; Buchanan DD; Jenkins MA; Schaeffer DF; Rosty C; Como J; Phipps AI; Newcomb PA; Burnett-Hartman AN; Le Marchand L; Samadder NJ; Patel B; Swallow C; Lindor NM; Gallinger SJ; Grant RC; Westerling-Bui T; Conner J; Cyr DP; Kirsch R; Pai RK
Gastroenterology; 2022 Dec; 163(6):1531-1546.e8. PubMed ID: 35985511
[TBL] [Abstract] [Full Text] [Related]
14. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract] [Full Text] [Related]
15. braf V600E mutations in right-side colon cancer: Heterogeneity detected by liquid biopsy.
Ueda K; Yamada T; Ohta R; Matsuda A; Sonoda H; Kuriyama S; Takahashi G; Iwai T; Takeda K; Miyasaka T; Shinji S; Chika N; Ishida H; Yoshida H
Eur J Surg Oncol; 2022 Jun; 48(6):1375-1383. PubMed ID: 35172933
[TBL] [Abstract] [Full Text] [Related]
16. Can Albumin Bilirubin Ratio and Inflammatory Prognostic Index Be A New Marker Determining Survival in Metastatic pancreatic cancer?
Ekinci F; Sarı D; Çelik C; Dirican A; Erdoğan AP; Gökse G
Gulf J Oncolog; 2021 May; 1(36):45-52. PubMed ID: 35017135
[TBL] [Abstract] [Full Text] [Related]
17. Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.
Nishioka Y; Paez-Arango N; Boettcher FO; Kawaguchi Y; Newhook TE; Chun YS; Tzeng CD; Tran Cao HS; Lee JE; Vreeland TJ; Vauthey JN
J Gastrointest Surg; 2022 Apr; 26(4):791-801. PubMed ID: 34725784
[TBL] [Abstract] [Full Text] [Related]
18. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
19. [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
Schlitter AM; Konukiewitz B; Kasajima A; Reichert M; Klöppel G
Pathologe; 2021 Sep; 42(5):464-471. PubMed ID: 34402977
[TBL] [Abstract] [Full Text] [Related]
20. The Transcription Factor SLUG Uncouples pancreatic cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway.
Bilal F; Arenas EJ; Pedersen K; Martínez-Sabadell A; Nabet B; Guruceaga E; Vicent S; Tabernero J; Macarulla T; Arribas J
Cancer Res; 2021 Jul; 81(14):3849-3861. PubMed ID: 33903121
[TBL] [Abstract] [Full Text] [Related]
[Next]
